Cell Therapy Yields Promising Results For Scleroderma Treatment PDF Print E-mail
Tuesday, 24 September 2013 08:49
Cytori Therapeutics, Inc. provided preliminary data from a study evaluating a potential treatment for Scleroderma based on the company's cell therapy. The investigator-funded, open-label, pilot study is being conducted on patients with Cutaneous Systemic Scleroderma in France.

12 patients were administered Cytori's cell therapy, injected into their fingers. Safety and hand function improvement are the primary endpoints of the study which were measured by the Cochin hand functional scale at six months.

At the end of the two month follow-up period, no infection, ischemic complications or serious adverse events were observed. Moreover, there was a significant improvement in the Cochin hand function disability scale.

As far as secondary endpoints are concerned, there was a significant improvement in Scleroderma health assessment questionnaire score and in Raynaud's Severity Score. Also, there was a significant improvement in hand pain when measured by the visual analog pain scale.

Cytori is focused primarily on the development of treatments for cardiovascular disease and soft tissue injuries and burns based on its proprietary cell therapy formulation. The company's cell therapy is based on the formulation of stem and regenerative cells derived from a patient's own adipose (fat) tissue (ADRCs).

Source: NASDAQ (2013)
 
More articles :

» Management

Our Management Team or Executive Committee is presently responsible for the daily operations of the Scleroderma Care Foundation, realizing its vision, and similarly ensuring its growth and future success. Adelwyn Holder, Co-Founder &...

» Prevention Of Vascular Damage In Scleroderma With Angiotensin-converting Enzyme (ACE) Inhibition

Great strides have been made in identifying and managing the organ-based complications of  systemic sclerosis (SSc). There is no room for the nihilism towards treating this disease that used to be so prevalent. However, there is still...

» What You Should Know About The AntiNuclear Antibody Or ANA Test

How is it used?The ANA test is ordered to help screen for autoimmune disorders and is most often used as one of the tests to diagnose (SLE). Depending on the patient's symptoms and the suspected diagnosis, ANA may be ordered along with one or more...

» Greater Global Cooperation and Collaboration in Scleroderma Research Required

Greater global cooperation and collaboration among Scleroderma researchers and clinicians would be all that is required to fuel a drive toward important discoveries and optimize outcomes for patients with this chronic, progressive, and often...

» Understanding Autoimmunity

What is Autoimmunity?One of the functions of the immune system is to protect the body by responding to invading microorganisms, such as viruses or bacteria, by producing antibodies or sensitized (types of white blood cells). Under normal...

» Geneticists Hunt for Scleroderma Triggers

In all its forms, gives Dartmouth geneticist Michael Whitfield, his graduate students, and his postdoctoral researchers a sense of urgency in their search for the triggers of the chronic condition. In a study that the Journal of Investigative...